Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Biotech Industry Analysis

UpdatedSep 29, 2025
DataAggregated Company Financials
Companies548
  • 7D-0.7%
  • 3M8.1%
  • 1Y-6.3%
  • YTD6.7%

Over the last 7 days, the Biotech industry has remained flat, although notably uniQure gained 292%. As for the longer term, the industry has declined 6.3% in the last year. Earnings are forecast to grow by 25% annually.

Industry Valuation and Performance

Has the U.S. Biotech Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Mon, 29 Sep 2025US$1.1tUS$163.5b-US$18,298,125,619.8316.3x-58.9x6.6x
Wed, 27 Aug 2025US$1.1tUS$163.6b-US$18,630,807,213.6115.3x-56.5x6.4x
Fri, 25 Jul 2025US$997.5bUS$155.2b-US$23,161,447,469.4316.9x-43.1x6.4x
Sun, 22 Jun 2025US$930.4bUS$155.9b-US$23,931,619,289.3716.8x-38.9x6x
Tue, 20 May 2025US$895.3bUS$155.9b-US$24,383,038,329.0316.1x-36.7x5.7x
Thu, 17 Apr 2025US$763.1bUS$119.2b-US$36,649,632,928.0519.4x-20.8x6.4x
Sat, 15 Mar 2025US$834.3bUS$118.4b-US$37,624,196,989.9318.5x-22.2x7x
Mon, 10 Feb 2025US$840.3bUS$117.3b-US$30,891,273,158.0417.2x-27.2x7.2x
Wed, 08 Jan 2025US$967.5bUS$149.6b-US$26,358,490,111.7216.5x-36.7x6.5x
Fri, 06 Dec 2024US$1.0tUS$150.0b-US$26,562,709,685.0617.5x-38.7x6.9x
Sun, 03 Nov 2024US$1.1tUS$147.4b-US$30,522,373,860.5217.5x-35x7.2x
Tue, 01 Oct 2024US$894.5bUS$113.2b-US$36,002,779,251.2421.3x-24.8x7.9x
Thu, 29 Aug 2024US$907.1bUS$113.1b-US$35,726,620,298.3524.2x-25.4x8x
Sat, 27 Jul 2024US$1.2tUS$164.9b-US$28,965,808,648.7626.4x-42.6x7.5x
Mon, 24 Jun 2024US$1.2tUS$164.4b-US$27,942,490,934.1228.1x-41.4x7x
Wed, 22 May 2024US$1.1tUS$164.6b-US$26,765,333,205.6424.5x-42.8x7x
Fri, 19 Apr 2024US$1.1tUS$164.2b-US$23,337,120,518.7320.4x-45.9x6.5x
Sun, 17 Mar 2024US$1.2tUS$167.4b-US$22,071,849,383.6413.9x-53.2x7x
Tue, 13 Feb 2024US$1.2tUS$169.3b-US$26,222,327,301.1520.4x-44.5x6.9x
Thu, 11 Jan 2024US$1.4tUS$204.8b-US$22,494,732,823.0019.3x-64.2x7.1x
Sat, 09 Dec 2023US$1.3tUS$204.6b-US$22,091,414,218.0018.7x-58.4x6.3x
Mon, 06 Nov 2023US$1.2tUS$206.7b-US$20,529,146,956.0018.8x-60.5x6x
Wed, 04 Oct 2023US$1.2tUS$207.3b-US$13,085,561,707.0016.6x-94.9x6x
Fri, 01 Sep 2023US$1.3tUS$207.6b-US$12,418,173,316.0017.4x-103.3x6.2x
Sun, 30 Jul 2023US$1.1tUS$186.0b-US$15,177,418,533.0014.7x-74.9x6.1x
Tue, 27 Jun 2023US$1.1tUS$186.2b-US$16,151,917,994.0013.4x-69.8x6.1x
Thu, 25 May 2023US$1.1tUS$185.9b-US$15,950,003,280.0011.5x-71.8x6.2x
Sat, 22 Apr 2023US$1.2tUS$198.4b-US$3,214,788,122.0013.9x-370.1x6x
Mon, 20 Mar 2023US$1.1tUS$199.2b-US$3,870,392,033.0013.2x-288.7x5.6x
Wed, 15 Feb 2023US$1.2tUS$202.8b-US$166,103,827.0016.3x-6973.2x5.7x
Fri, 13 Jan 2023US$1.2tUS$203.7bUS$1.8b14.5x658.8x5.8x
Sun, 11 Dec 2022US$1.1tUS$202.7bUS$1.4b14.6x811.7x5.6x
Tue, 08 Nov 2022US$1.1tUS$204.5bUS$3.9b14.4x280.2x5.3x
Thu, 06 Oct 2022US$1.1tUS$206.3bUS$5.5b15.3x193.7x5.2x
Price to Earnings Ratio

193.7x


Total Market Cap: US$1.1tTotal Earnings: US$5.5bTotal Revenue: US$206.3bTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Biotech Industry Price to Earnings3Y Average 32.8x202320242025
Current Industry PE
  • Investors are relatively neutral on the American Biotechs industry at the moment, indicating that they anticipate long term growth rates to remain steady.
  • The industry is trading close to its 3-year average PS ratio of 6.4x.
Past Earnings Growth
  • Total earnings for the Biotechs industry have declined over the last three years, with the industry now making a loss overall.
  • Revenues have also declined 7.5% per year, which is driving profits down.

Industry Trends

Which industries have driven the changes within the U.S. Healthcare industry?

US Market-0.97%
Healthcare-0.88%
Biotech-0.72%
Biotech-0.72%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
QURE uniQureUS$54.31292.7%
+US$3.1b		1,001.6%PS279.9x
SMMT Summit TherapeuticsUS$20.959.7%
+US$1.4b		-4.3%PB60x
UTHR United TherapeuticsUS$432.664.3%
+US$810.9m		20.7%PE15.8x
VRTX Vertex PharmaceuticalsUS$385.740.7%
+US$667.9m		-17.1%PE27.2x
SRRK Scholar Rock HoldingUS$38.7518.9%
+US$593.1m		383.8%PB16x

Latest News

ABBV
US$220.61
AbbVie
7D
-0.9%
1Y
11.7%

Expanding Immunology And Neuroscience Will Reshape Global Healthcare

AbbVie’s consensus price target has been raised from $217.45 to $227.22, as analysts highlight the value added by the extended Rinvoq patent runway, top- and bottom-line beats, pipeline expansion through the Bretisilocin acquisition, and underappreciated royalty streams. Analyst Commentary Bullish analysts cite a substantial extension of Rinvoq’s U.S. patent runway through favorable settlement, delaying generic entry until 2037—4 years beyond prior expectations—and modeling this as adding $11-$24 per share in value.
REGN
US$563.90
Regeneron Pharmaceuticals
7D
-5.3%
1Y
-46.4%
CDTX
US$90.50
Cidara Therapeutics
7D
31.7%
1Y
742.6%
QURE
US$54.31
uniQure
7D
292.7%
1Y
1,001.6%
VRTX
US$385.74
Vertex Pharmaceuticals
7D
0.7%
1Y
-17.1%
SRRK
US$38.75
Scholar Rock Holding
7D
18.9%
1Y
383.8%
SMMT
US$20.95
Summit Therapeutics
7D
9.7%
1Y
-4.3%
ALNY
US$446.40
Alnylam Pharmaceuticals
7D
-2.7%
1Y
62.3%

RNAi Therapies Will Ensure Worldwide Market Expansion

Alnylam Pharmaceuticals’ price target was raised to $447.15 as analysts cited accelerating Amvuttra sales, positive clinical progress, robust financial execution, and increased revenue forecasts, reflecting growing confidence in the company’s commercial momentum and pipeline. Analyst Commentary Strong commercial momentum for Amvuttra, particularly in ATTR-CM, with sales trends and script data consistently exceeding expectations.
INSM
US$137.03
Insmed
7D
-5.5%
1Y
87.7%
AMGN
US$272.98
Amgen
7D
-4.6%
1Y
-15.3%
UTHR
US$432.66
United Therapeutics
7D
4.3%
1Y
20.7%
NTRA
US$162.97
Natera
7D
-9.1%
1Y
28.4%
ONC
US$326.06
BeOne Medicines
7D
-3.5%
1Y
45.2%

Oncology Trials And Global Expansion Will Unlock Future Markets

BeOne Medicines’ consensus price target was raised to $367.68, reflecting analyst optimism driven by robust sales growth, positive pipeline updates, profitability, and increased revenue guidance. Analyst Commentary Bullish analysts highlight BeOne Medicines’ broad oncology pipeline and upcoming pivotal data readouts—specifically BTK inhibitor data in mantle cell lymphoma and PD1 inhibitor/anti-HER2 combination results in gastroesophageal cancer—as key drivers for durable growth.
CAI
US$29.19
Caris Life Sciences
7D
-11.4%
1Y
n/a
SLNO
US$64.96
Soleno Therapeutics
7D
14.8%
1Y
28.7%
MLTX
US$61.99
MoonLake Immunotherapeutics
7D
12.8%
1Y
22.9%

Is MoonLake Immunotherapeutics (NASDAQ:MLTX) Using Debt In A Risky Way?

Jul 26
Is MoonLake Immunotherapeutics (NASDAQ:MLTX) Using Debt In A Risky Way?